Kyverna Therapeutics (NASDAQ:KYTX) Reaches New 12-Month Low at $13.89

Kyverna Therapeutics, Inc. (NASDAQ:KYTX)’s share price reached a new 52-week low on Monday . The company traded as low as $13.89 and last traded at $13.89, with a volume of 166721 shares. The stock had previously closed at $15.25.

Analysts Set New Price Targets

A number of research firms have recently weighed in on KYTX. Wells Fargo & Company assumed coverage on shares of Kyverna Therapeutics in a report on Monday, March 4th. They set an “overweight” rating and a $44.00 target price for the company. Leerink Partnrs restated an “outperform” rating on shares of Kyverna Therapeutics in a report on Monday, March 4th. JPMorgan Chase & Co. assumed coverage on shares of Kyverna Therapeutics in a report on Monday, March 4th. They issued an “overweight” rating and a $39.00 price objective for the company. SVB Leerink assumed coverage on shares of Kyverna Therapeutics in a report on Monday, March 4th. They issued an “outperform” rating and a $48.00 price objective for the company. Finally, Morgan Stanley began coverage on shares of Kyverna Therapeutics in a report on Monday, March 4th. They issued an “overweight” rating and a $40.00 price objective for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $42.75.

Kyverna Therapeutics Trading Down 7.3 %

The company’s 50 day moving average is $22.74.

Insider Buying and Selling at Kyverna Therapeutics

In other Kyverna Therapeutics news, major shareholder Northpond Ventures Iii Gp, Llc bought 450,000 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was acquired at an average price of $22.00 per share, with a total value of $9,900,000.00. Following the completion of the purchase, the insider now owns 450,000 shares of the company’s stock, valued at $9,900,000. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kyverna Therapeutics stock. Jennison Associates LLC acquired a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,398,659 shares of the company’s stock, valued at approximately $34,743,000. Jennison Associates LLC owned about 3.24% of Kyverna Therapeutics as of its most recent SEC filing. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.